[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100559930":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":34,"centralContacts":35,"locations":34,"responsibleParty":45,"collaborators":34,"id":47,"slug":48,"hasResults":49,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":34,"eligibilityCriteria":53,"healthyVolunteers":54,"sex":55,"minAge":56,"maxAge":57,"enrollmentInfo":58,"targetDuration":34,"studyType":61,"phases":62,"briefSummary":64,"conditions":65,"keywords":67,"overallStatus":71,"whyStopped":34,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":34},{"fullName":5,"class":6},"Affiliated Cancer Hospital & Institute of Guangzhou Medical University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"ESPB Group","EXPERIMENTAL","The drug composition of the analgesic pump for erector spinae block was 300 mL of 0.25% ropivacaine, the mode was intermittent pumping, and the parameters were set as follows: 30 mL of the first dose, 5 mL\u002Fh of the background dose, and 10 mL of the pumping every 6h for the first 24 hours after the operation.",[13],"Drug: Ropivacaine",{"label":15,"type":16,"description":17,"interventionNames":18},"Convention group","ACTIVE_COMPARATOR","Intravenous analgesic is sufentanil ( 2.0 μg\u002Fkg), 0.9% saline diluted to 100 mL, background dose of 2 ml\u002Fh, no loading dose, activated after extubation and continued until 48 hours postoperatively.",[19],"Drug: Sufentanil",[21,28],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Ropivacaine","300 mL of 0.25% ropivacaine, the mode was intermittent pumping, and the parameters were set as follows: 30 mL of the first dose, 5 mL\u002Fh of the background dose, and 10 mL of the pumping every 6h for the first 24 hours after the operation.",[9],[27],"Erector spinae plane block",{"type":22,"name":29,"description":30,"armGroupLabels":31,"otherNames":32},"Sufentanil","Sufentanil 2.0 μg\u002Fkg, 0.9% saline diluted to 100 mL, background dose of 2 ml\u002Fh, no loading dose, activated after extubation and continued until 48 hours postoperatively.",[15],[33],"Intravenous analgesia",null,[36,41],{"name":37,"role":38,"phone":39,"phoneExt":34,"email":40},"Junqiang Hu, bachelor","CONTACT","17702007842","3336862127@qq.com",{"name":42,"role":38,"phone":43,"phoneExt":34,"email":44},"Yonghua Yao, master","13711568864","yaoyonghua01@126.com",{"type":46,"investigatorFullName":34,"investigatorTitle":34,"investigatorAffiliation":34,"oldNameTitle":34,"oldOrganization":34},"SPONSOR","100559930","early-phase-1-analgesic-efficacy-of-an-opioid-free-postoperative-pain-management-strategy-versus-a-conventional-opioid-based-strategy-following-video-assisted-thoracoscopic-lobectomy-100559930",false,"NCT06570538","Analgesic Efficacy of an Opioid-free Postoperative Pain Management Strategy Versus a Conventional Opioid-based Strategy Following Video-assisted Thoracoscopic Lobectomy","Analgesic Efficacy of an Opioid-free Postoperative Pain Management Strategy Versus a Conventional Opioid-based Strategy Following Video-assisted Thoracoscopic Lobectomy: an Open-label, Randomized, Controlled, Non-inferiority Trial","Inclusion criteria:\n\n* Aged between 18 and 65 years.\n* Patients with lung cancer or suspected lung cancer who are undergoing lobectomy surgery via Video-assisted thoracoscopic surgery (VATS) or Robotic-assisted thoracoscopic surgery (RATS).\n* American anesthesiologist association (ASA) physical status classificationⅠ-Ⅲ.\n* Surgery is expected to last at least 2 hours, with a minimum of 2 days of postoperative hospitalization.\n* Patients participate voluntarily and have signed an informed consent form.\n\nExclusion Criteria:\n\n* Patients who underwent open-heart surgery.\n* Patients with BMI ≥30 kg\u002Fm², or ≤18.5 kg\u002Fm².\n* Patients who are allergic to any of the local anesthetic drugs, such as ropivacaine, lidocaine, bupivacaine, procaine, bupivacaine, benzocaine, dacronin, etc.\n* Patients who are allergic to any of the general anesthesia drugs, such as those including propofol, sufentanil, remifentanil, etc.\n* Patients who currently have active ulcers or have gastrointestinal bleeding or who are allergic to any NSAIDs such as parecoxib sodium, flurbiprofenol ester, and acetaminophen.\n* Patients with contraindications to epidural spinal plane block (ESPB), such as skin infection near the puncture site or coagulation disorders.\n* Patients allergic to ultrasound gel.\n* Patients with significant preoperative renal insufficiency (creatinine more than twice the upper limit of normal).\n* Patients with severe spinal deformities prior to surgery.\n* Patients with preoperative distant tumor metastasis.\n* Patients who have experienced cardiovascular or cerebrovascular accidents within the past six months.\n* Patients with unstable angina, ischemic myocardial infarction, or heart failure in the last six months.\n* Patients with severe preoperative lung disease (such as pulmonary fibrosis, severe lung abscess, pulmonary heart disease; or with FEV1 less than 50% of the predicted value, PaO2 ≤ 60 mmHg, PaCO2 \\> 50 mmHg).\n* Patients with poorly controlled preoperative hypertension or diabetes mellitus.\n* Patients with a past history of dementia, psychosis, or other neurological disorders.\n* Patients undergoing concurrent treatment for other surgical conditions.\n* Patients taking sedatives, antidepressants, or hormonal medications.\n* Patients with chronic pain, alcoholism, or drug dependence.\n* Patients who are pregnant or breastfeeding\n* Patients with other potentially serious medical conditions.\n* Patients who are unable to understand Mandarin or Cantonese.\n* Patients who participated in other clinical trials in the past 3 months\n* Patients who refuse to participate in the study or sign the informed consent form.",true,"ALL","18 Years","65 Years",{"count":59,"type":60},140,"ESTIMATED","INTERVENTIONAL",[63],"EARLY_PHASE1","Investigators have designed a randomized controlled trial. Utilizing an open-label, randomized, controlled study methodology, this trial aims to explore a opioid-free, safe, and effective analgesic approach for thoracic surgery. It also seeks to provide clinical guidance for the implementation of opioid-free or reduced-opioid postoperative analgesia in other thoracic procedures, aiming to optimize postoperative pain management for patients and ultimately enhance the overall patients recovery experience.",[66],"Postoperative Pain",[68,69,70,27],"Lung Cancer","Postoperative pain","OFA","NOT_YET_RECRUITING","2024-08-22",{"date":74,"type":75},"2024-08-26","ACTUAL",{"date":77,"type":60},"2024-09-01",{"date":79,"type":60},"2025-06-30",{"name":5,"class":6}]